We have established a novel role for the second messenger DAG (diacylglycerol), a product of PtdIns(4,5)P 2 hydrolysis by PLC (phospholipase C). In addition to its well-known function as a protein kinase C activator, DAG produced by stimulation of the epidermal growth factor receptor causes the redistribution of the Rac-GAP (GTPase-activating protein) β2-chimaerin to the plasma membrane, where it associates with the active form of Rac1 and promotes the inactivation of this small G-protein. This represents the first example of a Rac-GAP regulated directly by DAG in response to the activation of a tyrosine kinase receptor, and suggests a previously unappreciated role for this lipid as a negative modulator of Rac signalling.
Introduction
For many years, it has been widely conceived that PKC (protein kinase C) is the only family of intracellular receptors for the lipid second messenger DAG (diacylglycerol) and their analogues, the phorbol esters. The fact that the C1 domain, a stretch of 50 amino acids responsible for DAG/phorbol ester binding, is also present in a number of proteins distinct from PKCs raised the possibility that DAG should trigger responses independently of PKC. The C1 domain is duplicated (C1A and C1B) in DAG-responsive PKCs, but is present as a single copy in a variety of molecules that include protooncogenes, G-protein regulators and adaptor proteins [1, 2] . However, only a subset of these C1 domain-containing proteins is capable of binding DAG and phorbol esters with high affinity due to strict structural requirements. In early 1990s, the laboratories of Lim [3] and Blumberg [4] reported that n-chimaerin (later renamed α1-chimaerin), a protein without kinase activity, binds [ 3 H]PDBu (phorbol 12,13-dibutyrate) in vitro with an affinity that was in the same range (nanomolar) as PKCs. Later studies determined that PKDs (protein kinases), RasGRPs (Ras guanine nucleotide-releasing protein), Munc-13s and DAG kinases also bind this radioligand with high affinity in a phospholipid-dependent fashion. Most of these molecules possess a single C1 domain, and therefore it became clear that one copy of the motif was sufficient to confer DAG responsiveness [2, [5] [6] [7] [8] [9] . These findings have remarkable biological and pharmacological implications. On the one hand, they suggest the possibility of divergence in DAG signalling via 'non-PKC' DAG effectors. On the other hand, it becomes clear that drugs designed to target C1 domains, such as the anticancer agent bryostatin I, may not be PKC-specific. While the complexity in phorbol ester/DAG signalling is far beyond our current understanding, recent advances have clarified that each of the DAG receptors has unique regulatory properties and distinct patterns of expression. Increasing evidence suggests that there is no unifying mechanism for their intracellular activation. As C1 domains may not be always exposed, as recently determined for β2-chimaerin [10] , it is likely that in some cases activation of C1 domain-containing proteins is preceded by other inputs that facilitate the access to the lipid second messenger.
Chimaerins as phorbol ester receptors
The chimaerin family of phorbol ester receptors comprises four isoenzymes (α1-, α2-, β1-and β2-chimaerins). In addition to a single C1 domain, chimaerins possess a C-terminal domain with Rac-GAP (GTPase-activating protein) activity that accelerates GTP hydrolysis from Rac, a small G-protein that is involved in the control of cell cytoskeleton reorganization, migration and proliferation. α2-and β2-chimaerins have in addition a SH2 domain in the N-terminal region. β1-and β2-chimaerins are alternative spliced products of the β-chimaerin gene (CHN2), as are α1-chimaerin and α2-chimaerin from the α-chimaerin gene (CHN1) [2] .
Early studies from our laboratory have demonstrated that recombinant β2-chimaerin produced in Sf9 cells binds [ 3 H]PDBu with high affinity in the presence of acidic phospholipids. Binding is lost when the essential Cys 246 in the C1 domain is mutated to alanine. DAG analogues displace [ 3 H]PDBu from β2-chimaerin in competition assays [11, 12] . These experiments clearly defined that, as in the case of PKCs, the C1 domain in β2-chimaerin is responsible for DAG binding. Moreover, like phorbol ester-responsive PKCs, β2-chimaerin could be translocated to the plasma membrane by phorbol ester analogues. Translocation of β2-chimaerin is fully dependent on the integrity of the C1 domain, as redistribution of the protein to the periphery is not observed with the mutant C246A-β2-chimaerin [12, 13] . An interesting observation is that β2-chimaerin also redistributes to a perinuclear compartment in response to PMA. By using a yeast two-hybrid approach, we identified the Golgi/ endoplasmic reticulum protein Tmp21-I as a chimaerininteracting protein. The Tmp21-I-β2-chimaerin interaction could be enhanced by PMA in a dose-dependent manner.
Interaction between Tmp21-I and β2-chimaerin also strictly depends on the integrity of the β2-chimaerin C1 domain [14] . Interestingly, PKCε interacts with the Golgi protein β -COP (coat protein) [15] , and the phorbol ester/DAG receptor Munc-13 also translocates to the Golgi network after phorbol ester treatment [16] . A speculation is that Tmp21-I may be part of an anchoring complex not only for chimaerins but also for other DAG receptors. As the molecular basis of the C1 domain-Tmp21-I association is yet unknown, one hypothesis is that specificity for the interaction is driven by distinct residues within the C1 domains.
β2-Chimaerin inhibition of Rac-mediated responses
Rac1, a member of the Rho GTPase family, plays a very important role in controlling actin dynamics, cell cycle, cell adhesion, gene transcription, vesicle transport and cell polarity [17, 18] . Activation of Rac by membrane receptors is mediated by GEFs (guanine nucleotide-exchange factors).
In vitro studies showed that β2-chimaerin has GAP activity specifically towards Rac, as it accelerates the hydrolysis of GTP from Rac1, but not from Cdc42 (cell division cycle 42) or RhoA [19] . This specificity has been confirmed in cellular models for β2-chimaerin and other chimaerin isoforms. Overexpression studies in breast cancer cells revealed that β2-chimaerin inhibits Rac-mediated responses, such as EGF (epidermal growth factor)-or heregulin β1-induced actin cytoskeleton reorganization and migration [20, 21] . Moreover, mammary carcinoma cells expressing the C-terminal β-GAP (β2-chimaerin GAP domain) show reduced Rac1-GTP levels and slower proliferation rates, an effect that is not observed with a GAP-deficient mutant [20, 22] . Ectopic expression of β-GAP also reduces the invasive and metastatic ability of breast cancer cells, a response consistent with the Rac-GAP activity of the protein [20] .
β2-Chimaerin as an effector of the EGFR (EGF receptor) via the PLCγ (phospholipase Cγ ) pathway
While the properties of chimaerins as phorbol ester receptors have been known for years, a crucial question that remained unanswered was whether chimaerins were responsive to DAG generated by receptor stimulation. Phorbol ester and DAG responses are not necessarily equivalent due to their differential stability and half-life in cellular models. Generation of DAG by PLC upon receptor stimulation is rapid and short-lived, and the affinity of DAG for C1 domains is much lower than that of PMA. Recent studies shed light on this important issue, as they established that α-and β-chimaerins are indeed effectors of tyrosine kinase receptors (such as EGFR) and GPCRs (G-protein-coupled receptors) linked to G q [23] [24] [25] . It is very well documented that EGFR activates a wide range of signalling pathways that control cell growth, survival and motility. Upon ligand binding, EGFR undergoes autophosphorylation, and distinctive phosphotyrosine motifs in its cytoplasmic tail act as docking sites for both adaptors and effector signalling molecules. Phosphorylated tyrosine in position 992 drives the recruitment of PLCγ to the EGFR [26] . Activated PLCγ promotes the breakdown of the membrane lipid PtdIns(4,5)P 2 into InsP 3 and DAG. EGF also leads to Rac activation via PI3K-dependent activation of RacGEFs [27] . Therefore a likely scenario is that in response to EGFR stimulation DAG regulates chimaerins positionally to promote their association with their target Rac. Thus the EGFR represented an excellent paradigm to assess the role of chimaerins in a physiological context.
A fundamental question was whether EGF could translocate chimaerins to the plasma membrane, as phorbol esters did. To address this issue, we expressed GFP (green fluorescent protein)-β2-chimaerin in various cellular models (HeLa and COS-1 cells) and monitored its redistribution by time-lapse confocal microscopy. A time-dependent redistribution of GFP-β2-chimaerin to the cell periphery was observed in response to EGF. Translocation was better appreciated by co-expression of the plasma membrane marker RFP-CAAX. A similar pattern was observed with the endogenous protein in Neuro-2A cells. The peripheral redistribution of β2-chimaerin by EGF was impaired both by pharmacological inhibition of PLC or depletion of PLCγ 1 using RNAi (RNA interference), arguing for a fundamental role of DAG in regulating translocation. Translocation in response to EGF was not observed for the DAG-unresponsive mutant GFP-C246A-β2-chimaerin. Interestingly, the GAPdeficient mutant EIE-β2-chimaerin (deletion in positions 298-300) showed a much pronounced translocation in response to EGF. A hypothesis was that reduction in Rac-GTP levels caused by β2-chimaerin in the membrane contributes to the reversal of such redistribution, arguing for a role of Rac-GTP in sustaining the association of β2-chimaerin with the plasma membrane. It seems, however, that this scenario is unlikely because a dominant-negative Rac (N17-Rac1) was unable to reverse β2-chimaerin translocation. It also became clear that translocation was independent of ruffle formation [25] .
Association of β2-chimaerin with Rac1 in the plasma membrane in response to EGF proved to be difficult to measure by co-immunoprecipitation, most probably because of the transient nature of DAG generation and the rapid hydrolysis of Rac-GTP caused by β2-chimaerin. In order to overcome this limitation, we developed an FRET (fluorescence resonance energy transfer) assay in COS-7 cells to monitor this interaction in a dynamic fashion, using the pair CFP (cyan fluorescent protein)-Rac1 and YFP (yellow fluorescent protein)-β2-chimaerin. Significant FRET in the cell periphery was detected upon EGF treatment in a time-dependent manner. PMA also caused significant FRET, an effect that was more sustained than that observed in response to receptor activation. FRET was not observed when the following pairs were used: CFP/YFP, CFPRac1/YFP, CFP/β2-chimaerin and CFP/ EIE-YFP-β2-chimaerin. The association of Rac1 and β2-chimaerin measured by FRET was severely impaired by inhibition or depletion of PLCγ . As expected, replacement of Cys 246 by alanine in the β2-chimaerin C1 domain abolished FRET. Taken together, these results argue for a strict dependence of the Rac1-β2-chimaerin interaction on the EGFR-PLCγ -DAG axis. Interestingly, and in agreement with the translocation experiments, sustained FRET in response to EGF was observed in cells co-expressing CFP-Rac1 and the GAP-deficient mutant YFP-EIE-β2-chimaerin [25] .
The relevance of β2-chimaerin as an EGFR effector was further strengthened using RNAi. Depletion of β2-chimaerin by delivery of a specific siRNA (small interfering RNA) duplex into HEK-293 cells (human embryonic kidney cells; which express β2-chimaerin) led to prolonged Rac1 activation in response to EGF. Rac1 activation by EGF was also extended upon dual depletion of α2-and β2-chimaerin isoforms in HeLa cells [25] .
Conclusion
Our studies determined that the Rac-GAP β2-chimaerin is recruited to the plasma membrane through the EGFR-PLCγ -DAG axis, leading to down-regulation of Rac activity (Figure 1) . These results establish a novel role for the lipid second messenger DAG as a negative regulator of Rac signalling. Recent studies have also extended these observations to GPCRs. Siliceo et al. [23] reported that in T-lymphocytes, DAG generated upon activation of the CXCR4 (CXC chemokine receptor 4) receptor (which couples with PLCβ) translocates β2-chimaerin to the plasma membrane. Similarly, peripheral localization of α1-chimaerin has been observed in response to the activation of muscarinic receptors in hippocampal neurons [24] . The ability of DAG to negatively modulate Rac responses may have significant implications in neuronal function and cancer. The zebrafish chimaerin homologue was recently found to modulate epiboly progression [28] , a mechanism in which Rac has been also implicated [29] , suggesting that DAG-mediated inhibition of Rac function may also have major implications in development.
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